Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on precision psychiatry. It develops personalized treatments for neuropsychiatric disorders such as major depressive disorder, bipolar depression, and schizophrenia using its proprietary Precision Psychiatry Platform. The platform integrates neurobiological data and machine learning to identify biomarkers for targeted patient populations. Alto’s pipeline includes novel small molecules and repurposed drugs designed to improve treatment efficacy and patient outcomes in CNS disorders.
This description was generated via AI from an annual report. Updated about 1 year ago.